Activity Preview


Optimal ICD Programming and Testing: Strategies and Highlights from the International Consensus Document

Activity Type:

  • On-Demand

This activity has expired

Release Date: 6/9/2016

Expiration Date: 6/14/2017

  • Participation - no CE credit: 0


This on-demand activity is:

  • Complimentary for HRS members
  • $29 USD for non-members

The HRS/EHRA/APHRS/SOLAECE Expert Consensus Statement on Optimal Implantable Cardioverter-Defibrillator Programming and Testing provides more than 30 recommendations for strategic programming and testing of ICDs. Learn how to implement these recommendations in your clinical practice by viewing the following presentations:

Top Takeaways (10 minutes)
- Summary of consensus methodology and formulation of the recommendations
Implementation: US and European Perspectives (15 minutes)
- Review of the recommendations and implications for patient care
- Strategies for implementation in different geographical regions
Manufacturer-Specific Translations of Recommendations (10 minutes)
- Development and application of Appendix B
ICD Programming & Remote Monitoring (10 minutes)
- Presentation by the Chair of the 2015 HRS Expert Consensus Statement on Remote Interrogation and Monitoring for CIEDs
- Explore the relationship between the two consensus documents
Panel Discussion (30 minutes)
- Panel discussion on implementation, accountability and the consensus process recorded at HRS Scientific Sessions 2016


Learning Objectives

After completing this activity, participants will be able to:

  • Apply a strategic, standardized approach to ICD programming based on the latest consensus recommendations
  • Consider remote and in-person interrogations when making programming choices


Laurent Fauchier, MD, PhD

A - Compensation for Services; 1; Medtronic, Inc., Bayer, Novartis, Pfizer, Boehringer Ingelheim. B - Speakers Bureau; 1; Bayer, Pfizer, Boehringer Ingelheim, Boston Scientific Corp., Daiichi Sankyo, Medtronic, Inc., Novartis

Carlos Morillo, MD, FRCPC, FHRS

A - Compensation for Services; 1; Sanofi Aventis, Biotronik. A - Compensation for Services; 2; Boehringer Ingelheim, Merck Pharmaceuticals. B - Speaker's Bureau; 1; Boehringer Ingelheim, Sanofi Aventis, Bayer HealthCare, LLC. B - Speaker's Bureau; 2; Merck Pharmaceuticals. I - Research Grants; 0; Canadian Institute of Health Research, Pfizer, Inc., Boston Scientific Corp. I - Research Grants; 3; St. Jude Medical. I - Research Grants; 4; Medtronic, Inc., Boston Scientific Corp.

David Slotwiner, MD, FHRS


Martin Stiles, MBCHB, PhD

A - Compensation for Services; 1; Medtronic, Inc., Boston Scientific Corp., Biotronik, Biosense Webster, Inc. J - Fellowship Support; 2; Medtronic, Inc. J - Fellowship Support; 3; Biosense Webster, Inc., St. Jude Medical. 

Bruce Wilkoff, MD, FHRS, CCDS

A - Compensation for Services; 1; St. Jude Medical, Boston Scientific Corp. A - Compensation for Services; 2; Spectranetics Corporation, Medtronic, Inc.. E - Royalty Income; 2; Medtronic, Inc.